首页> 外文期刊>Nanomedicine Journal >BSA nanoparticles loaded with IONPs for biomedical applications: fabrication optimization, physicochemical characterization and biocompatibility evaluation
【24h】

BSA nanoparticles loaded with IONPs for biomedical applications: fabrication optimization, physicochemical characterization and biocompatibility evaluation

机译:负载用于生物医学应用的IONP的BSA纳米颗粒:制备优化,理化特性和生物相容性评估

获取原文
           

摘要

Objective(s): Cancer diagnosis in its early stages of progress, can enhance the efficiency of treatment utilizing conventional therapy methods. Non-biocompatibility of iron oxide nanoparticles (IONPs) has made a big challenge against their usage as a contrast agent. Efficient coverage by biomolecules such as albumin can be a solution to overcome this problem. Herein, albumin-coated IONPs were prepared and the process was optimized using the response surface methodology (RSM) to achieve optimum loading of IONPs in albumin nanoparticles. Materials and Methods: IONPs were incorporated into bovine serum albumin nanoparticles (BSA NPs) matrix, to yield IONPs-BSA NPs. The resulting nanoparticles were characterized physicochemically by scanning electron microscopy (SEM), dynamic light scattering (DLS), inductively coupled plasma optical emission spectrometry (ICP-OES), Fourier transform infrared spectroscopy (FTIR) and vibrating sample magnetometer (VSM). The stability test was conducted over 6 months.Results: Under optimum conditions of 2.28 mg for iron weight and pH 9.21, loading of 7.76% was obtained for the spherical IONPs-BSA NPs with the size of 177±12 nm, PDI of 0.222±0.07 and zeta-potential of -36.4±2.3 mV. These findings revealed that more than 90% and 60% of the particles retained their size over four and six months of storage at 4 °C, respectively. In addition, non-cytotoxicity and hemocompatibility of IONPs-BSA NPs were verified in vitro thereby offering them as a biocompatible contrast agent for cancer diagnosis. Conclusion: The IONPs-BSA NPs developed in this study are promising to be further investigated and functionalized with a ligand to obtain a targetable MRI contrast agent for early cancer diagnosis.
机译:目标:癌症诊断处于早期发展阶段,可以提高使用常规治疗方法的治疗效率。氧化铁纳米粒子(IONPs)的非生物相容性对它们用作造影剂提出了巨大挑战。生物分子(例如白蛋白)的有效覆盖可以解决该问题。本文中,制备了白蛋白包被的IONP,并使用响应表面方法(RSM)对工艺进行了优化,以实现IONP在白蛋白纳米颗粒中的最佳负载。材料和方法:将IONPs掺入牛血清白蛋白纳米颗粒(BSA NPs)基质中,得到IONPs-BSA NPs。通过扫描电子显微镜(SEM),动态光散射(DLS),电感耦合等离子体发射光谱(ICP-OES),傅立叶变换红外光谱(FTIR)和振动样品磁力计(VSM)对所得纳米颗粒进行物理化学表征。进行了6个月的稳定性测试。结果:在铁重量为2.28 mg,pH为9.21的最佳条件下,球形IONPs-BSA NP的载量为7.76%,尺寸为177±12 nm,PDI为0.222± 0.07和ζ电位-36.4±2.3 mV。这些发现表明,超过90%和60%的颗粒分别在4°C的四个月和六个月内保持其大小。此外,已在体外验证了IONPs-BSA NP的无细胞毒性和血液相容性,从而将其作为生物相容性造影剂用于癌症诊断。结论:本研究开发的IONPs-BSA NP有望进一步研究并与配体一起功能化,以获得可用于早期癌症诊断的可靶向MRI造影剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号